Stoke Therapeutics (NASDAQ:STOK) Insider Arthur Tzianabos Sells 4,355 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Arthur Tzianabos sold 4,355 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the sale, the insider directly owned 31,339 shares of the company’s stock, valued at $1,253,560. This represents a 12.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Trading Down 6.9%

STOK stock traded down $2.53 during mid-day trading on Friday, hitting $33.95. The stock had a trading volume of 739,715 shares, compared to its average volume of 729,700. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $40.22. The firm has a market capitalization of $1.94 billion, a P/E ratio of 51.02 and a beta of 1.07. The firm has a fifty day simple moving average of $32.66 and a 200 day simple moving average of $29.46.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. UBS Group set a $50.00 target price on Stoke Therapeutics in a research note on Monday, December 15th. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Guggenheim began coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective for the company. Wedbush raised their price objective on Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.25.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the fourth quarter valued at approximately $26,000. Harbour Investments Inc. grew its holdings in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $41,000. BNP Paribas Financial Markets raised its stake in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.